Abstract: Objective To study the safety of oxaliplatin for injection in patients with gastric cancer. Methods The process of treating one 51-year-old male patient who developed generalised myalgia as a result of postoperative chemotherapy for a malignant tumor after being given oxaliplatin was analyzed. Results The laboratory test tests were as follows: the level of carbohydrate antigen was 19-9 (CA19-9) 6.09 U·mL^-1, CA72-4 was 2.6 U·mL^-1, CA15-3 was 6.99 U·mL^-1, carcinoembryonic antigen was 2.45 ng·mL^-1, alpha fetoprotein was 1.76 ng·mL^-1, creatine kinase (CK) was 49 U·L^-1, and serum creatinine (SCr) was 83 μmoL·L^-1. After other causes of generalized myalgia were ruled out, the possibility of adverse reactions being caused by oxaliplatin was taken into account. Upon discontinuation of oxaliplatin, the patient reported reduced muscle soreness, with a VAS score of 7. One week later, the patient’s muscle soreness completely disappeared, resulting in a VAS score of 0. Conclusion Oxaliplatin for injection may increase the risk of generalised muscle pain, so clinical vigilance is required.

Key words: oxaliplatin, injection, myalgia, adverse drug reaction, gastric cancer, chemotherapy, tumor